Tyrosine kinase inhibitors (TKIs) are nowadays a valuable treatment of desmoid tumors, a rare mesenchymal neoplasm. Although many side effects of imatinib and pazopanib, commonly or rarely occurring, have been described, reactional lymphadenopathy has not yet been reported. In this publication, we report two cases of patients with desmoid tumors, treated with pazopanib and imatinib, who developed reactional lymphadenopathy. As this side effect is presented as a newly formed mass, it can result in new diagnostic questions and added imaging tests and can even lead to discontinuation of the treatment. This report may help the clinicians facing similar problems adopt a "watch and wait" approach.
Keywords: case report; desmoid tumors; lymphadenopathy; pazopanib; side effects; tyrosine kinase inhibitor.
Copyright © 2022 Papadopoulos, Koulouris, Royer-Chardon, Tsoumakidou, Dolcan, Cherix, Matter, Omoumi and Digklia.